US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00% AVGO $362.51 ▲+0.00%
FinancialContent

Immunome, Inc. - Common Stock (NQ:IMNM)

21.17 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
News headline image
Evaluating Immunome: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Stock Sees RS Rating Jump To 91 ↗
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
News headline image
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024 ↗
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
News headline image
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immunome Announces Completion of Purchase of Assets from Atreca
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
From Immunome, Inc.
Via Business Wire
News headline image
IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 ↗
IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at 2024 Bank of America Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Kinney Horn as Chief Business Officer
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Sandra M. Swain to Board of Directors
From Immunome
Via Business Wire
News headline image
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
News headline image
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 ↗
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
News headline image
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday? ↗
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >